Evidence map›Paper›PMID 29110129›Full record

Observational studyEndocrine2018

Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.

G Mazziotti, A M Formenti, M B Panarotto, E Arvat, A Chiti, A Cuocolo, M E Dottorini, C Durante, L Agate, S Filetti and 13 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 1 country.

G MazziottiEndocrine Unit, ASST Carlo Poma, Mantua, Italy.
A M FormentiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
M B PanarottoNuclear Medicine, ASST Spedali Civili of Brescia, Brescia, Italy.
E ArvatOncological Endocrinology, University of Turin, Torino, Italy.
A ChitiNuclear Medicine, Humanitas Research Hospital and Humanitas University, Milan, Italy.
A CuocoloNuclear Medicine, University of Naples Federico II, Napoli, Italy.
M E DottoriniNuclear Medicine, "S. Maria della Misericordia" Hospital, Perugia, Italy.
C DuranteInternal Medicine, University Sapienza of Rome, Roma, Italy.
L AgateEndocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
S FilettiInternal Medicine, University Sapienza of Rome, Roma, Italy.
F FelicettiOncological Endocrinology, University of Turin, Torino, Italy.
A FiliceNuclear Medicine, Azienda Ospedaliera Santa Maria Nuova-IRCCS Reggio Emilia, Reggio Emilia, Italy.
L PaceDepartment of Medicine and Surgery, University of Salerno, Fisciano, Italy.
T PellegrinoInstitute of Biostructure and Bioimaging of the National Research Council of Italy-CNR, Naples, Italy.
M RodariNuclear Medicine, Humanitas Research Hospital and Humanitas University, Milan, Italy.
M SalvatoriNuclear Medicine, Catholic University of Sacred Heart, Rome, Italy.
C TranfagliaNuclear Medicine, "S. Maria della Misericordia" Hospital, Perugia, Italy.
A VersariNuclear Medicine, Azienda Ospedaliera Santa Maria Nuova-IRCCS Reggio Emilia, Reggio Emilia, Italy.
D ViolaEndocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
S FraraSan Raffaele Vita-Salute University, Milan, Italy.
A BerrutiMedical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
A GiustinaSan Raffaele Vita-Salute University, Milan, Italy. giustina.andrea@hsr.it.
R GiubbiniNuclear Medicine, ASST Spedali Civili of Brescia, Brescia, Italy.
University of Brescia · ITAzienda Ospedaliera di Perugia · ITAzienda Ospedaliera S.Maria · ITHumanitas University · ITSapienza University of Rome · ITUniversity of Pisa · ITUniversity of Turin · ITVita-Salute San Raffaele University · ITAzienda Ospedaliera Carlo Poma · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITInstitute of Biostructure and Bioimaging · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Naples Federico II · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose and patientsThe M.O.S.CA.TI. (Metastases of the Skeleton from CArcinoma of the ThyroId) is a multicenter, retrospective study investigating the real-life outcome and management of bone metastases (BM) in 143 patients (63 M, 80 F; median age 64 years, range 11-87) with differentiated thyroid carcinoma (DTC).

resultsRadio-active iodine (RAI) treatment was performed in 131 patients (91.6%), surgical approach and/or external radiotherapy in 68 patients (47.6%), and anti-resorptive bone-active drugs in 32 patients (22.4%; in 31 zoledronate and in one denosumab). At the start of treatment, 24 patients (75.0%) receiving anti-resorptive bone-active drugs had at least one clinical skeletal-related event (SRE) (p < 0.001). One or more clinical SREs (pathological fractures and/or malignant hypercalcemia and/or spinal cord compression) developed in 53 patients (37.1%). Development of SREs was significantly associated with metachronous BM (hazard ratio (HR) 2.04; p = 0.04), localization of BM to cervical spine (HR 3.89; p = 0.01), and lack of avid RAI uptake (HR 2.66; p = 0.02). Thirty-nine patients (27.3%) died in correlation with development of SREs (HR 6.97; p = 0.006) and localization of BM to the hip (HR 3.86; p = 0.02). Moreover, overall mortality was significantly decreased by RAI therapy (HR 0.10; p = 0.02), whereas no significant effects were induced by bone-active drugs (p = 0.36), external radiotherapy (p = 0.54), and surgery (p = 0.43) of BM.

conclusionsSREs are very frequent in BM from DTC and they impact patient survival. In the real life, the use of bone-active drugs is currently limited to zoledronate in patients with pre-existing SREs. In this clinical setting, RAI therapy, but not zoledronate, decreased mortality.

Indexed as

AdolescentAdultAgedAged, 80 and overBone NeoplasmsChildFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesThyroid NeoplasmsTreatment OutcomeYoung AdultBone metastasesDenosumab-radioiodineThyroid carcinomaZoledronate

Identifiers

PMID29110129
OpenAlexW2765084664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.